Combining the specificity and stability of antibodies with the potency of small molecules has always been at the core of the antibody-drug conjugate (ADC) field. The technological challenge to this therapeutic approach is in bringing two disparate molecules in union with one another. Once this was achieved, the next technological hurdle was, in essence, automation (1).
Early versions of an ADC were the product of technical skill which also required trial and error. Bioconjugation experts investigated many combinations of antibodies, small molecule drugs, conditions, and reaction times to produce stable and efficacious final drugs. This work serves as a technical knowledge base from which to convert new antibodies into ADCs. Even with compendium textbooks like Bioconjugate Techniques, trial and error is still required especially to manufacture an ADC at clinical scale.
Corresponding Authors: Derrick Houser. E-mail: Derrick Houser and Scott Beaver, Ph.D. E-mail: Scott Beaver, Ph.D.
Key terms: ADC, bioconjugation, automation, bioconjugation techniques
Published In: ADC Review| Journal of Antibody-drug Conjugates
How to cite:
Houser D. 1 and Beaver S. 1 2 Automating ADC Manufacturing with Electricity – J. ADC. April 10, 2023. DOI: 10.14229/jadc.2023.04.10.001.
1 Express biolabs
Last Editorial Review: March 31, 2023
- Original Manuscript Received January 24, 2023
- Review results received March 23, 2022
- Manuscript accepted for publication April 10, 2023